AR051759A1 - Formulaciones de compuestos de acido boronico en liposomas - Google Patents

Formulaciones de compuestos de acido boronico en liposomas

Info

Publication number
AR051759A1
AR051759A1 ARP050104638A ARP050104638A AR051759A1 AR 051759 A1 AR051759 A1 AR 051759A1 AR P050104638 A ARP050104638 A AR P050104638A AR P050104638 A ARP050104638 A AR P050104638A AR 051759 A1 AR051759 A1 AR 051759A1
Authority
AR
Argentina
Prior art keywords
liposomes
boronic acid
liposomas
formulations
trapped
Prior art date
Application number
ARP050104638A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR051759A1 publication Critical patent/AR051759A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe una composicion de liposomas compuesta por liposomas que tienen un compuesto peptídico de ácido boronico inhibidor el proteasoma atrapado en los liposomas. El compuesto de ácido boronico está atrapado en los liposomas en forma de éster de boronato, como consecuencia de la interaccion con un poliol atrapado en los liposomas. En una realizacion, los liposomas tienen un revestimiento externo de cadenas poliméricas hidrofilas y se los utiliza para tratar un tumor solido en un sujeto.
ARP050104638A 2004-11-05 2005-11-04 Formulaciones de compuestos de acido boronico en liposomas AR051759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62521604P 2004-11-05 2004-11-05

Publications (1)

Publication Number Publication Date
AR051759A1 true AR051759A1 (es) 2007-02-07

Family

ID=35947260

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104638A AR051759A1 (es) 2004-11-05 2005-11-04 Formulaciones de compuestos de acido boronico en liposomas

Country Status (21)

Country Link
US (2) US20060153907A1 (es)
EP (2) EP1807053A1 (es)
JP (2) JP2008519041A (es)
KR (2) KR20070085642A (es)
CN (2) CN101094648A (es)
AR (1) AR051759A1 (es)
AU (2) AU2005304881A1 (es)
BR (2) BRPI0517061A (es)
CA (2) CA2586348A1 (es)
CR (1) CR9168A (es)
EA (1) EA200701005A1 (es)
IL (1) IL182967A0 (es)
MX (2) MX2007005499A (es)
NI (1) NI200700120A (es)
NO (1) NO20072830L (es)
NZ (2) NZ554950A (es)
PE (1) PE20061135A1 (es)
TW (1) TW200618820A (es)
UY (1) UY29191A1 (es)
WO (2) WO2006052733A1 (es)
ZA (1) ZA200705017B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
WO2009047639A2 (en) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Epicatechin deficient green tea
SG10201508712QA (en) * 2007-08-06 2015-11-27 Millenium Pharmaceuticals Inc Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CA2697044A1 (en) * 2007-08-21 2009-02-26 Alza Corporation Liposome formulations of boronic acid compounds
JP2010536874A (ja) * 2007-08-21 2010-12-02 アルザ・コーポレーシヨン ボロン酸化合物をインビボ投与するためのリポソーム組成物
EP2733147A1 (en) 2008-06-17 2014-05-21 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
KR100918776B1 (ko) * 2009-04-20 2009-09-24 계명대학교 산학협력단 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
KR101530942B1 (ko) * 2010-03-18 2015-06-23 이노파르마, 인코포레이티드 안정한 보르테조밉 포뮬레이션
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
IT1403157B1 (it) 2010-12-01 2013-10-04 Elbi Int Spa Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio.
ES2913069T3 (es) * 2011-03-02 2022-05-31 Sensulin Llc Composiciones de vesículas
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
WO2014092858A1 (en) 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US20160129117A1 (en) 2013-07-03 2016-05-12 Nippon Kayaku Kabushiki Kaisha Novel Boronic Acid Compound Preparation
WO2015117136A1 (en) * 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
WO2015179443A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals. Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2017014130A (es) * 2015-05-04 2018-07-06 Versantis AG Metodo para preparar vesiculas con gradiente de ph de transmembrana.
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN107922609B (zh) 2015-07-01 2020-04-24 加州理工学院 基于阳离子粘酸聚合物的递送系统
CN104958768A (zh) * 2015-07-17 2015-10-07 中国科学院长春应用化学研究所 一种葡聚糖-硼替佐米键合药及其制备方法
WO2017031084A1 (en) * 2015-08-14 2017-02-23 The Regents Of The University Of California Poly(vinyl alcohol) nanocarriers
BR112018077015B1 (pt) 2016-06-30 2022-05-03 Qpex Biopharma, Inc Derivados de ácido borônico e usos terapêuticos dos mesmos
US10583083B1 (en) * 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US20200261596A1 (en) 2016-10-20 2020-08-20 Pfizer Inc. Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
WO2019023092A1 (en) * 2017-07-24 2019-01-31 Pharmosa Biopharm Inc. LIPOSOME COMPOSITIONS COMPRISING LOW ACID BASED MEDICAMENTS AND USES THEREOF
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN110540547A (zh) 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
US20220362268A1 (en) * 2019-10-07 2022-11-17 Cornell University Antimicrobial and antiviral effects of c2-c7 alkyl boronic acids
US20240173374A1 (en) * 2021-02-25 2024-05-30 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN112915094A (zh) * 2021-03-26 2021-06-08 东南大学 一种硼替佐米脂质体制剂的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5047245A (en) * 1985-07-26 1991-09-10 The Liposome Company, Inc. Novel composition for targeting, storing and loading of liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
DK0555229T3 (da) * 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
WO1996032930A1 (en) * 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
AU4907897A (en) * 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6110491A (en) * 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
BR9914601A (pt) * 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
WO2001005873A1 (en) * 1999-07-14 2001-01-25 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
AU1658401A (en) * 1999-11-19 2001-05-30 Topgene, Inc. Boron compounds and complexes as anti-inflammatory agents
DK1355910T3 (da) * 2001-01-25 2011-06-27 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulering af borsyreforbindelser
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
WO2004043374A2 (en) * 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors

Also Published As

Publication number Publication date
MX2007005499A (es) 2007-09-21
CR9168A (es) 2008-11-24
BRPI0517668A (pt) 2008-10-14
IL182967A0 (en) 2007-08-19
US20060153907A1 (en) 2006-07-13
PE20061135A1 (es) 2006-10-20
MX2007005497A (es) 2007-09-21
NO20072830L (no) 2007-07-24
UY29191A1 (es) 2006-01-31
KR20070085644A (ko) 2007-08-27
WO2006052733A1 (en) 2006-05-18
CA2586348A1 (en) 2006-05-18
ZA200705017B (en) 2008-09-25
CN101094649A (zh) 2007-12-26
NZ554951A (en) 2010-12-24
NZ554950A (en) 2010-12-24
EA200701005A1 (ru) 2007-10-26
JP2008519040A (ja) 2008-06-05
BRPI0517061A (pt) 2008-09-30
EP1807052A1 (en) 2007-07-18
EP1807053A1 (en) 2007-07-18
US20060159736A1 (en) 2006-07-20
KR20070085642A (ko) 2007-08-27
AU2005304881A1 (en) 2006-05-18
TW200618820A (en) 2006-06-16
JP2008519041A (ja) 2008-06-05
NI200700120A (es) 2008-05-15
WO2006052734A1 (en) 2006-05-18
CA2586354A1 (en) 2006-05-18
CN101094648A (zh) 2007-12-26
AU2005304880A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
AR051759A1 (es) Formulaciones de compuestos de acido boronico en liposomas
NI201000030A (es) Formulaciones de liposomas de compuestos de ácidos borónico
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ECSP14010763A (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
ECSP109981A (es) Composiciones de liposomas para administración in vivo de compuestos de ácido borónico
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
HN2003000039A (es) 2-(PIRIMIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
PE20110297A1 (es) Inhibidores de dpp-4 para la cicatrizacion de heridas
ECSP056082A (es) Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
ATE541975T1 (de) Lichtemittierender getufteter teppich
AR063853A1 (es) Metodo para tratar el cabello
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
AR057181A1 (es) Nueva forma de dosificacion de combinacion
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
TW200740719A (en) Pyrene organic compound, transistor material and light emitting transistor element
CO6511274A2 (es) Estabilización de peliculas de oxido de zinc en composiciones bucales
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
PE20091456A1 (es) Nuevas formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)-5-tert-butil-pirazol-1-il]benzoico- 471
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
ECSP088889A (es) Forma nueva de administración de racecadotril

Legal Events

Date Code Title Description
FB Suspension of granting procedure